Search results for "Thrombosis."

showing 10 items of 624 documents

The influence of gestational diabetes mellitus (GDM) and gestational hypertension (GH) on placental morphological changes

2020

Gestational diabetes mellitus (GDM) and gestational hypertension (GH) are some of the most common medical conditions associated with pregnancy. These can be correlated with placental morphopathological changes and implicitly can influence good fetal development. The age and weight of the mother can be correlated directly proportionally with those of the fetus but also with histoarchitecture and placental vascularization. The placental appearance associated with GDM and GH reveals macroscopic features, such as calcifications, fibrin deposits and placental infarcts, but the most relevant pathological features are the microscopic ones, highlighted by the classical staining techniques: Hematoxy…

Gestational hypertensionAdultEmbryologyPathologymedicine.medical_specialtyEndotheliumplacentaAdolescent030209 endocrinology & metabolism030204 cardiovascular system & hematologyFibrinPathology and Forensic Medicinechorangiosis03 medical and health sciencesYoung Adult0302 clinical medicinePregnancymedicineHumansPathologicalPregnancyFetusOriginal Paperbiologybusiness.industryhypoxiaCell BiologyGeneral MedicineHypertension Pregnancy-InducedMiddle Agedmedicine.diseaseThrombosisGestational diabetesDiabetes Gestationalmedicine.anatomical_structurefibrin depositionsbiology.proteinFemalebusinessDevelopmental BiologyRomanian Journal of Morphology and Embryology
researchProduct

The gut microbiota - a modulator of endothelial cell function and a contributing environmental factor to arterial thrombosis.

2019

Introduction: There is emerging evidence linking the commensal gut microbiota with the development of cardiovascular disease and arterial thrombosis. In immunothrombosis, the host clotting system protects against the dissemination of invading microbes, not considering the huge number of microbes that interact with host physiology in a mutualistic fashion. Areas covered: Interestingly, recent research revealed that colonizing gut microbes profoundly influence host innate immune pathways that support arterial thrombus growth. The gut microbiota promotes arterial thrombus formation by enhancing the pro-adhesive capacity of the vascular endothelium, triggering hepatic von Willebrand factor synt…

Gut floraEnvironment03 medical and health sciences0302 clinical medicineVon Willebrand factorCell AdhesionMedicineAnimalsHumansPlateletPlatelet activationImmunologic SurveillanceToll-like receptorInnate immune systembiologybusiness.industryEndothelial CellsThrombosisHematologyArteriesmedicine.diseasebiology.organism_classificationThrombosisGastrointestinal MicrobiomeEndothelial stem cell030220 oncology & carcinogenesisImmunologybiology.proteinDisease SusceptibilityEndothelium VascularbusinessBiomarkers030215 immunologyExpert review of hematology
researchProduct

Center for Thrombosis and Hemostasis Mainz.

2019

Hemostasisbusiness.industryInterdisciplinary ResearchCardiologyThrombosismedicine.diseaseThrombosisPatient careHemostasisGermanymedicineHumansCenter (algebra and category theory)Medical emergencyCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Testing for goodness rather than lack of fit of an X–chromosomal SNP to the Hardy-Weinberg model

2019

The problem of checking the genotype distribution obtained for some diallelic marker for compatibility with the Hardy-Weinberg equilibrium (HWE) condition arises also for loci on the X chromosome. The possible genotypes depend on the sex of the individual in this case: for females, the genotype distribution is trinomial, as in the case of an autosomal locus, whereas a binomial proportion is observed for males. Like in genetic association studies with autosomal SNPs, interest is typically in establishing approximate compatibility of the observed genotype frequencies with HWE. This requires to replace traditional methods tailored for detecting lack of fit to the model with an equivalence test…

HeredityNormal DistributionDistance MeasurementTrinomial01 natural sciencesLinkage Disequilibrium010104 statistics & probabilityStatisticsLack-of-fit sum of squaresMathematicsVenous ThrombosisMeasurement0303 health sciencesMultidisciplinaryQRSoftware EngineeringGenomicsHardy–Weinberg principleGenetic MappingPhysical SciencesEngineering and TechnologyMedicineResearch ArticleComputer and Information SciencesScienceGeometryAsymptotic distributionVariant GenotypesPolymorphism Single NucleotideMolecular Genetics03 medical and health sciencesGenome-Wide Association StudiesGeneticsTest statisticHumansComputer Simulation0101 mathematicsMolecular BiologyGenetic Association Studies030304 developmental biologyChromosomes Human XModels StatisticalModels GeneticSoftware ToolsBiology and Life SciencesComputational BiologyHuman GeneticsGenome AnalysisProbability TheoryProbability DistributionGenotype frequencyRadiiSample size determinationSample SizeBinomial proportion confidence intervalMathematicsPLOS ONE
researchProduct

The patient with autoimmune disorders

2021

InfertilityDisease activityPregnancyLupus Flarebusiness.industryAntiphospholipid syndromeImmunologymedicinemedicine.diseasebusinessThrombosisAnti-SSA/Ro autoantibodiesAssisted Reproduction Techniques
researchProduct

CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models

2021

BACKGROUND: CD248 is a pro-inflammatory, transmembrane glycoprotein expressed by vascular smooth muscle cells (VSMC), monocytes/macrophages, and other cells of mesenchymal origin. Its distribution and properties are reminiscent of those of the initiator of coagulation, tissue factor (TF). OBJECTIVE: We examined whether CD248 also participates in thrombosis. METHODS: We evaluated the role of CD248 in coagulation using mouse models of vascular injury, and by assessing its functional interaction with the TF-factor VIIa (FVIIa)-factor X (FX) complex. RESULTS: The time to ferric chloride-induced occlusion of the carotid artery in CD248 knockout (KO) mice was significantly longer than in wild-typ…

InflammationFactor VIIa030204 cardiovascular system & hematologyInferior vena cavaArticleThromboplastin03 medical and health sciencesTissue factorchemistry.chemical_compoundMice0302 clinical medicineThrombinTissue factor pathway inhibitorAntigens CDAntigens NeoplasmmedicineAnimalsHumansMice KnockoutVenous Thrombosismedicine.diagnostic_testFactor XHematologyCoagulationchemistrymedicine.veinCancer researchProthrombin Timemedicine.symptommedicine.drugPartial thromboplastin time
researchProduct

Inflammation as a therapeutic target in acute ischemic stroke treatment.

2009

Animal models of focal ischaemia induced by middle cerebral artery occlusion (MCAO) provide most evidence for cellular inflammatory responses in stroke. Permanent MCAO results in a modest neutrophil infiltration at 24 h after ischaemia, predominantly around arterial vessels at the margins of infarction, whereas MCAO with subsequent reperfusion is associated with substantial infiltration by neutrophils throughout the entire infarct. Several studies show that C-reactive protein (CRP), an inflammatory marker, is associated with stroke outcomes and future vascular events. Several drugs, especially hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), have been demonstrated to reduce …

InflammationProgrammed cell deathEndotheliumbusiness.industrymedicine.medical_treatmentIschemiaAnti-Inflammatory AgentsInflammationStimulationGeneral Medicinemedicine.diseaseThrombosisBrain IschemiaStrokeCytokinemedicine.anatomical_structureApoptosisDrug DiscoveryImmunologymedicineAnimalsCytokinesmedicine.symptombusinessCurrent topics in medicinal chemistry
researchProduct

Unexpected role of natural killer cell-derived interferon-γ as a driver of NETosis and DVT.

2018

Killer Cells NaturalVenous ThrombosisInterferon-gammamedicine.anatomical_structureInterferon γChemistrymedicineCancer researchHumansHematologyExtracellular TrapsNatural killer cellJournal of thrombosis and haemostasis : JTH
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference.

2016

Abstract Patients with cirrhosis present with hemostatic alterations secondary to reduced availability of pro-coagulant and anti-coagulant factors. The net effect of these changes is a rebalanced hemostatic system. The Italian Association of the Study of the Liver (AISF) and the Italian Society of Internal Medicine (SIMI) promoted a consensus conference on the hemostatic balance in patients with cirrhosis. The consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Rome in December 2014. The statements were graded according to quality of evidence and strength of recommendations, and approved by an independent …

Liver CirrhosisCirrhosisBleeding; Cirrhosis; Hemostasis; Thrombosis; Hepatology; GastroenterologySettore MED/09 - Medicina InternaBleeding; Cirrhosis; Hemostasis; Thrombosis; Anticoagulants; Coagulants; Drug Monitoring; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Postoperative Hemorrhage; Thrombosis; Blood Coagulation Tests; Hemostasis; Hepatology; Gastroenterology0302 clinical medicineEsophageal and Gastric VariceBlood coagulation testConsensus conferenceGastroenterologyThrombosisOptimal managementCirrhosisCoagulant030220 oncology & carcinogenesisThrombosi030211 gastroenterology & hepatologyBlood Coagulation TestsDrug MonitoringGastrointestinal HemorrhageHumanmedicine.medical_specialtyLiver CirrhosiBleeding; Cirrhosis; Hemostasis; Thrombosis; Gastroenterology; HepatologyPostoperative HemorrhageEsophageal and Gastric VaricesNO03 medical and health sciencesInternal medicinemedicineHumansIn patientIntensive care medicineHemostasisCirrhosiHepatologybusiness.industryCoagulantsBleeding; Cirrhosis; Hemostasis; ThrombosisBleedingAnticoagulantAnticoagulantsThrombosisHepatologyHemostasiBlood Coagulation Testmedicine.diseaseSurgeryHemostasisbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct